Clinical trials

Several clinical studies are currently ongoing within the I-BFM SG.

Here you find short summaries of a selection of these studies:

ALL

AIEOP-BFM ALL 2017 (2017 – ): Randomized clinical trial for ALL (age 1-18y)

EsPhALL2017-COGAALL1631: Randomized trial for patients with Ph+ ALLAIEOP-BFM ALL 2017 (2017-2023): Randomized clinical trial (age 1.0-21.9y)

ALLTogether-1 (2021 – ): Randomized clinical trial for ALL (age up to 45 years)

ALL-IC 2022 (3/2023 – ): Randomized clinical trial for ALL in countries with limited resources

Interfant-21 (2/2023 – ): Non-randomized clinical trial for all pts under 1y of age with KMT2A rear. ALL

 

AML

– ML-DS 2018: for newly diagnosed Down syndrome patients with myeloid leukemia

– AMoRe 2017: for molecular relapsed AML patients

– AIEOP-AML-BFM 2020: frontline protocol (BFM, AIEOP)

– ICC APL study 02: for newly diagnosed APL patients

– NOPHO-DBH AML 2012: frontline protocol (NOPHO DH SHIP)

– MyeChild01: frontline protocol (SFCE, CCLG, Ireland, Australia, Switzerland)

– AAML1831: frontline protocol (COG)

– JPLSG-AML-20: frontline protocol (JCCG)

– JPLSG-AML-P13: for newly diagnosed APL patients (JCCG)

– JPLSG-AML-D16: for newly diagnosed Down syndrome patients with myeloid leukemia (JCCG)

– PedAL trials for relapsed AML patients and early phase trials for relapsed AML (COG)

– EuPAL trials for relapsed AML patients and early phase trials for relapsed AML (ITCC)

 

CML

 

Bosutinib Study ITCC-054/AAML1921
Ponatinib Paediatric INCB84344-102 Study
Asciminib CABL001I12201 – ASC4KIDS

 

ELTEC

 

Projects in close collaboration with other committees in the field of early toxicity:

  • Supportive care in leukaemia treatment
  • Toxicity issues in NHL
  • Middle and late term toxicity in ALL
  • Prevention, Diagnosis & Management of Thrombosis & Bleeding in Children with Acute Lymphoblastic Leukaemia: European Survey of Current Practice

Projects in the field of late toxicity inside I-BFM :

  • Survey on your knowledge about your disease and later care

Projects in the field of late toxicity in collaboration with PanCare:

  • PanCareLife
  • Survivorship Passport

 

 

NHL

 

NHL-BFM and NOPHO trial: B-NHL 2013 study in mature B-cell neoplasms

EICNHL/i-BFM trial: LBL 2018 study in lymphoblastic lymphoma

EICNHL trial: ALCL-VBL study in SR ALK-pos. ALCL

 

SCT

ALL SCT PED 2012 Forum (for omitting radiation under majority age). Allogeneic Stem Cell Transplantation in Children and Adolescents with ALL in CR. Prospective controlled randomized international study:

  • Principal investigator: Christina Peters, E-mail: peters@stanna.at
  • Participating countries: Austria, Argentina, Australia, Chile, Czech Republic. Denmark, Finland, France, Germany, Greece, Hong-Kong, Hungary, Japan, Israel, Italy, The Netherlands, New Zealand, Norway, Polland, Slovakia, Sweden, Spain, Switzerland, Turkey, United Kingdom, USA
  • The study is open for international recruitment. Randomization is closed.